The acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory effects of ME and HWE were moderate and comparable with galanthamine, the standard drug to treat early stages of Alzheimer’s disease (AD). The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.